News | November 06, 2009

BIOTRONIK Announces Results of REPLACE Registry

November 4, 2009 — BIOTRONIK Inc. this week announced the results from site preparation, antibiotic use and infection sub-analysis from the REPLACE Registry. The results, based on analysis of 1,031 patients undergoing elective replacement of their implanted cardiac rhythm management (CRM) device, provides important insight on techniques for surgical site preparation and antibiotic use in device-replacement procedures.

The REPLACE Registry was designed to evaluate the rate of complications from CRM device replacement and upgrade from all CRM manufacturers. The REPLACE Registry is the first large, prospective study to look at the factors that influence infection rates in device replacement.

The sub-analysis included 1,031 replacement procedures with representative devices from five CRM manufacturers. The infection rates from the first group of patients in the REPLACE Registry were presented at the poster sessions of the Infectious Diseases Society of America Scientific Sessions. Two factors were identified that exhibited significantly different infection rates. The first factor was preoperative skin preparation. Skin preparation with povidone-iodine was associated with an increased rate of infection (2.1 percent) compared with chlorhexidine-containing compounds (0.2 percent). The second factor was post-operative antibiotic use. The incidence of infection among patients receiving no postoperative antibiotics (0.5 percent) was lower than in those receiving parenteral antibiotics postoperatively (2.3 percent).

“Postoperative IV antibiotics are often given to patients in an attempt to decrease the risk of infection,” noted Daniel Uslan, M.D., assistant clinical professor at UCLA and member of the REPLACE Registry steering committee. “In the REPLACE Registry, there did not seem to be any benefit to doing so.”

“Infections occurred uncommonly in the REPLACE Registry. It is interesting that a variety of antibiotic prophylaxis measures were used by the site investigators who participated,” added Jeanne Poole, M.D., national principal investigator for the REPLACE Registry. “All patients received intravenous antibiotics. These data will contribute significantly to the body of literature available on device related infections.”

For more information: www.biotronik.com

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Overlay Init